Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Cellular Immunity of SARS-CoV-2 in the Borriana COVID-19 Cohort: A Nested Case-Control Study

Version 1 : Received: 17 February 2024 / Approved: 20 February 2024 / Online: 20 February 2024 (09:01:39 CET)

A peer-reviewed article of this Preprint also exists.

Domènech-Montoliu, S.; Puig-Barberà, J.; Pac-Sa, M.R.; Orrico-Sanchéz, A.; Gómez-Lanas, L.; Sala-Trull, D.; Domènech-Leon, C.; Del Rio-González, A.; Sánchez-Urbano, M.; Satorres-Martinez, P.; Aparisi-Esteve, L.; Badenes-Marques, G.; Blasco-Gari, R.; Casanova-Suarez, J.; Gil-Fortuño, M.; Hernández-Pérez, N.; Jovani-Sales, D.; López-Diago, L.; Notari-Rodríguez, C.; Pérez-Olaso, O.; Romeu-Garcia, M.A.; Ruíz-Puig, R.; Arnedo-Pena, A. Cellular Immunity of SARS-CoV-2 in the Borriana COVID-19 Cohort: A Nested Case–Control Study. Epidemiologia 2024, 5, 167-186. Domènech-Montoliu, S.; Puig-Barberà, J.; Pac-Sa, M.R.; Orrico-Sanchéz, A.; Gómez-Lanas, L.; Sala-Trull, D.; Domènech-Leon, C.; Del Rio-González, A.; Sánchez-Urbano, M.; Satorres-Martinez, P.; Aparisi-Esteve, L.; Badenes-Marques, G.; Blasco-Gari, R.; Casanova-Suarez, J.; Gil-Fortuño, M.; Hernández-Pérez, N.; Jovani-Sales, D.; López-Diago, L.; Notari-Rodríguez, C.; Pérez-Olaso, O.; Romeu-Garcia, M.A.; Ruíz-Puig, R.; Arnedo-Pena, A. Cellular Immunity of SARS-CoV-2 in the Borriana COVID-19 Cohort: A Nested Case–Control Study. Epidemiologia 2024, 5, 167-186.

Abstract

Our goal was to determine the cellular immune response (CIR) among a random sample of the Borriana COVID-19 cohort (Spain) to identify its associated factors and their relationship with infection, reinfection and sequelae. We conducted a nested case-control study using a randomly selected sample of 225 individuals age 18 and older, including 36 individual naïve to SARS-CoV-2 infection, and 189 infected patients. We employed flow cytometry-based immunoassays for intracellular cytokine staining, utilizing Wuhan and BA.2 antigens and chemoluminescence microparticle immunoassay for detection SARS-CoV-2 antibodies. Logistic regression models were used. A total of 215 (95.6%) participants exhibited T-cell response (TCR) to at least one antigen. Positive responses of CD4+ and CD8+ T cells were 89.8% and 85.3% respectively. No difference in CIR was found for naïve and infected patients. Patients who experienced sequelae exhibited higher CIR than those without. A positive correlation was observed between TCR and Anti-Spike IgG levels. Factors positive associated with TCR included A-blood group, number of SARS-CoV-2 vaccine doses received, and Anti-N IgM; factors inversely related were the time elapsed since the last vaccine dose or infection, and B-blood group. These findings contribute valuable insights into the nuance immune landscape shaped by SARS-CoV-2 infection and vaccination.

Keywords

COVID-19; SARS-CoV-2 infection; cellular immunity; T cells; CD4+; CD8+; humoral immunity; Anti-S antibodies Anti-N antibodies; nested case-control; associated factors

Subject

Medicine and Pharmacology, Epidemiology and Infectious Diseases

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.